Delayed Diagnosis of Bacteriologically Positive Pulmonary Tuberculosis and Relative Optimized Suggestions in China
Condition:   Tuberculosis; Pulmonary, Confirmed, Unspecified Means Intervention:   Sponsor:   Huashan Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 17, 2020 Category: Research Source Type: clinical trials

Xpert MTB/RIF Test in the Diagnosis of Pulmonary Tuberculosis
Condition:   Pulmonary Tuberculosis Confirmation by Culture Intervention:   Diagnostic Test: Xpert MTB/RIF test Sponsors:   Taipei Medical University WanFang Hospital;   Buddhist Tzu Chi General Hospital;   Chest Hospital, Ministry of Health and Welfare, Taiwan;   Chang-Hua Hospital;   Taichung Veterans General Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 16, 2020 Category: Research Source Type: clinical trials

Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation
Conditions:   Latent Tuberculosis;   Diabetes Mellitus, Type 2 Interventions:   Drug: Rifampicin 300 Mg Oral Capsule;   Drug: Isoniazid 300 MG Sponsor:   Herlev and Gentofte Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 12, 2020 Category: Research Source Type: clinical trials

Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II)
AbstractObjectivesTo assess the safety and therapeutic effects of allogeneic human dental pulp stem cells (DPSCs) in treating severe pneumonia caused by COVID-19.Trial designThis is a single centre, two arm ratio 1:1, triple blinded, randomized, placebo-controlled, parallel group, clinical trial.ParticipantsTwenty serious COVID-19 cases will be enrolled in the trial from April 6th to December 31st 2020. Inclusion Criteria: hospitalised patients at Renmin Hospital of Wuhan University satisfy all criteria as below:Adults aged 18-65 years;Voluntarily participate in this clinical trial and sign the “informed consent form...
Source: Trials - June 11, 2020 Category: Research Source Type: clinical trials

Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation
Conditions:   Latent Tuberculosis;   Diabetes Mellitus, Type 2 Interventions:   Drug: Rifampicin 300 Mg Oral Capsule;   Drug: Isoniazid 300 MG Sponsor:   Herlev and Gentofte Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2020 Category: Research Source Type: clinical trials

Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
Condition:   Multidrug Resistant Tuberculosis Intervention:   Drug: Delamanid Sponsor:   Beijing Chest Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials

The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
Conditions:   HIV-1-infection;   Tuberculosis Interventions:   Drug: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid;   Drug: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid;   Drug: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz Sponsors:   Willem Daniel Francois Venter;   University of Cape Town Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials

Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
Condition:   Multidrug Resistant Tuberculosis Intervention:   Drug: Delamanid Sponsor:   Beijing Chest Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials

The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
Conditions:   HIV-1-infection;   Tuberculosis Interventions:   Drug: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid;   Drug: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid;   Drug: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz Sponsors:   Willem Daniel Francois Venter;   University of Cape Town Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials

Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
Condition:   Multidrug Resistant Tuberculosis Intervention:   Drug: Delamanid Sponsor:   Beijing Chest Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials

The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
Conditions:   HIV-1-infection;   Tuberculosis Interventions:   Drug: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid;   Drug: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid;   Drug: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz Sponsors:   Willem Daniel Francois Venter;   University of Cape Town Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials

Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
Condition:   Multidrug Resistant Tuberculosis Intervention:   Drug: Delamanid Sponsor:   Beijing Chest Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials

The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
Conditions:   HIV-1-infection;   Tuberculosis Interventions:   Drug: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid;   Drug: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid;   Drug: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz Sponsors:   Willem Daniel Francois Venter;   University of Cape Town Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials

Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
Condition:   Multidrug Resistant Tuberculosis Intervention:   Drug: Delamanid Sponsor:   Beijing Chest Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials

The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
Conditions:   HIV-1-infection;   Tuberculosis Interventions:   Drug: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid;   Drug: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid;   Drug: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz Sponsors:   Willem Daniel Francois Venter;   University of Cape Town Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials

Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
Condition:   Multidrug Resistant Tuberculosis Intervention:   Drug: Delamanid Sponsor:   Beijing Chest Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials

The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
Conditions:   HIV-1-infection;   Tuberculosis Interventions:   Drug: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid;   Drug: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid;   Drug: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz Sponsors:   Willem Daniel Francois Venter;   University of Cape Town Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials

Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
Condition:   Multidrug Resistant Tuberculosis Intervention:   Drug: Delamanid Sponsor:   Beijing Chest Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials

The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
Conditions:   HIV-1-infection;   Tuberculosis Interventions:   Drug: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid;   Drug: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid;   Drug: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz Sponsors:   Willem Daniel Francois Venter;   University of Cape Town Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials

Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
Condition:   Multidrug Resistant Tuberculosis Intervention:   Drug: Delamanid Sponsor:   Beijing Chest Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials

The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
Conditions:   HIV-1-infection;   Tuberculosis Interventions:   Drug: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid;   Drug: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid;   Drug: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz Sponsors:   Willem Daniel Francois Venter;   University of Cape Town Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials

To Assess the Efficiency and Satisfaction of Pharmacist Giving Patient-centred Advice on Telephone Consultation in TB Patients: Experience of the COVID-19 Pandemic
Conditions:   TB - Tuberculosis;   Patient Satisfaction Intervention:   Behavioral: Patient-centred advice on Telephone Consultation in TB Patients: Sponsors:   Health Science Center of Xi’an Jiaotong University;   Pakistan Institute of Medical Sciences Islamabad Pakistan;   District Headquarter Hospital Bannu Pakistan Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 2, 2020 Category: Research Source Type: clinical trials